从遗传风险到肾脏疾病的转变的生物标志物。
"Biomarking" the transition from genetic risk to kidney disease.
机构信息
Department of Nephrology, Rambam Health Care Campus, Haifa, Israel.
Department of Nephrology, Rambam Health Care Campus, Haifa, Israel; Department of Genetics and Developmental Biology, Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
出版信息
Kidney Int. 2018 Jun;93(6):1270-1272. doi: 10.1016/j.kint.2018.03.005.
Only some individuals carrying the high-risk APOL1 genotype go on to develop kidney disease phenotypes. In this issue of Kidney International, Nadkarni and colleagues report the associations of several biomarkers with renal outcomes in individuals with high-risk APOL1 genotypes. In the era of precision medicine, these findings should translate into improved longitudinal risk assessment for this high-risk population and might also provide additional insights regarding sites and mechanisms of APOL1 nephropathy.
只有少数携带高危 APOL1 基因型的个体才会发展为肾脏疾病表型。在本期《国际肾脏杂志》中，Nadkarni 及其同事报告了几种生物标志物与高危 APOL1 基因型个体的肾脏结局之间的关联。在精准医学时代，这些发现应该可以改善对这一高危人群的纵向风险评估，并且可能还提供有关 APOL1 肾病的发病部位和机制的更多见解。
Zotero 插件